Trial Profile
Phase 3 study of TAK-536 (confirmatory trial)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Candesartan cilexetil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- 23 Mar 2011 Secondary endpoint 'Systolic-blood-pressure' has been met
- 23 Mar 2011 Secondary endpoint 'Diastolic-blood-pressure' has been met
- 23 Mar 2011 Secondary endpoint 'Ambulatory-blood-pressure' has been met